药明生物开建全球领先的抗体偶联药物（ADC）一体化研发生产中心
药明生物开建全球领先的抗体偶联药物（ADC）一体化研发生产中心
WuXi Biologics Initiated Construction of a State-of-the-Art Integrated ADC Solution Center
(*Please scroll down for English news.)
中国无锡，2018年6月20日
全球领先的生物制药技术平台公司药明生物（WuXi Biologics, 2269.HK）今日宣布，公司计划投资2,000万美元在无锡国家高新技术产业开发区筹建全球领先的生物偶联药物一体化研发生产中心。
签约仪式现场
【无锡市副市长、高新区党工委书记、新吴区委书记王进健先生（左七），无锡高新区党工委副书记、管委会副主任洪延炜先生（右六），药明生物首席技术官、高级副总裁周伟昌博士（左六）出席签约仪式】
这是药明生物计划建设的第三个生物制剂生产基地（Drug Product 3, DP3），旨在为国内外合作伙伴提供包括抗体偶联药物（Antibody-Drug Conjugates, ADCs）在内的生物偶联药物（Biologics-Drug Conjugates）一体化研发生产服务，推动全球创新生物偶联药物从概念到商业化生产的研发全过程。该中心规划建筑面积达6,000平方米，预计将于2019年完工并投入使用。
抗体偶联药物（ADCs）是一类通过连接子（Linker）将具有肿瘤细胞杀伤力的小分子药物（Drug）偶联至单克隆抗体（Antibody）上而产生的复杂药物，也是近年来肿瘤靶向治疗领域的一种新兴疗法。药明生物将把该中心打造成为符合美国、欧盟以及中国cGMP标准的国际一流抗体偶联药物研发生产平台，从而更好地服务全球合作伙伴。
“我非常高兴能在抗体偶联药物领域开展新投资。”药明生物首席执行官陈智胜博士表示，“借助与药明康德集团旗下化学药业务部门的通力合作，药明生物将成为全球范围内为数不多能提供从抗体、活性小分子、抗体偶联药物原液到制剂一站式服务的企业。我们致力于为全球合作伙伴赋能，帮助他们开发任意一种抗体偶联药物，造福全球病患。”
关于药明生物
药明生物作为一家香港上市公司，是全球领先的开放式、一体化生物制药能力和技术赋能平台。公司为全球生物制药公司和生物技术公司提供全方位的端到端研发服务，帮助任何人、任何公司发现、开发及生产生物药，实现从概念到商业化生产的全过程，加速全球生物药研发进程，降低研发成本，造福病患。如需更多信息，请访问：www.wuxibiologics.com.cn。
更多阅读
WuXi Biologics Initiated Construction of a State-of-the-Art Integrated ADC Solution Center
WUXI, China, June 20, 2018
WuXi Biologics (2269.HK), a leading global open-access biologics technology platform company offering end-to-end solutions for biologics discovery, development and manufacturing, announced today that it has started the construction of a state-of-the-art integrated biologics conjugate solution center in Wuxi city, China.
This $20 million 6,000 square meter facility will be operational in 2019 and provide integrated solutions from concept to commercialization for biologics conjugates including Antibody-Drug Conjugates (ADCs) and other protein conjugates.
ADCs are complex molecules composed of an antibody linked to a biologically active cytotoxic drug and are becoming emerging treatments of targeted tumor therapy. WuXi Biologics plans to build this site into a world-class ADC R&D and manufacturing platform which will meet US, EU and Chinese cGMP standards.
“I am very excited about this new investment in ADCs,” Dr. Chris Chen, CEO of WuXi Biologics said. “In collaboration with chemistry division of WuXi AppTec Group, WuXi Biologics is one of the few global companies that can provide the one-stop service to global partners for antibodies, small molecule payloads, ADCs drug substance and drug products. Our vision is to empower any global partners to develop any ADC to benefit patients.”
About WuXi Biologics
WuXi Biologics, a Hong Kong-listed company, is the only open-access biologics technology platform in the world offering end-to-end solutions to empower organizations to discover, develop and manufacture biologics from concept to commercial manufacturing. Our company history and achievements demonstrate our commitment to providing a truly ONE-stop service offering and value proposition to our global clients. For more information on WuXi Biologics, please visit www.wuxibiologics.com.
注：本信息不构成药明生物的信息披露或投资建议